Imidazol derivatives as Raf kinase inhibitors

Details Imidazol derivatives as Raf kinase inhibitors Imidazol derivatives as Raf kinase inhibitors

2007-06-26

2007-06-26

Wilson, James O. (Department: 1623)

Organic compounds -- part of the class 532-570 series

Organic compounds

Four or more ring nitrogens in the bicyclo ring system

C546S255000

Reexamination Certificate

active

10220674

ABSTRACT:
Compounds of formula (I):whereinX is O, CH2, S or NH, or the moiety X—R1is hydrogen;V is CH or N;R1is hydrogen, C1-6alkyl, C3-7cycloalkyl, aryl, arylC1-6alkyl, heterocyclyl, heterocyclylC1-6alkyl, heteroaryl, or heteroarylC1-6alkyl any of which except for hydrogen may be optionally substituted;R2and R3independently represent optionally substituted C1-6alkyl, or R2and R3together with the carbon atom to which they are attached form an optionally substituted C3-7cycloalkyl or C3-7cycloalkenyl ring; or R2and R3together with the carbon atom to which they are attached form an optionally substituted 5 to 7-membered heterocyclyl ring containing up to 3 heteroatoms selected from N, O, S.R4and R5independently represent hydrogen, C1-6alkyl, C3-7cycloalkyl, aryl, arylC1-6alkyl, heteroaryl, heteroarylC1-6alkyl, heterocyclyl, or heterocyclylC1-6alkyl, any of which except for hydrogen may be optionally substituted or R4and R5together with the nitrogen atom to which they are attached form 4- to 8-membered ring;Ar is an aryl or heteroaryl ring either of which may be optionally substituted;one of X1and X2is N and the other is NR6, wherein R6is hydrogen, C1-6alkyl, or arylC1-6alkylor pharmaceutically acceptable salts thereof, their use as inhibitors of Raf kinases, and pharmaceutical compositions containing them.

REFERENCES:
patent: 4447431 (1984-05-01), Sallmann
patent: 5236917 (1993-08-01), Dunlap et al.
patent: 5514505 (1996-05-01), Limburg et al.
patent: 5717100 (1998-02-01), Selnick et al.
patent: 5859041 (1999-01-01), Liverton et al.
patent: 6548520 (2003-04-01), Adams et al.
patent: 2003/0134837 (2003-07-01), Gaiba et al.
patent: 2003/0153588 (2003-08-01), Steadman et al.
patent: 2004/0038964 (2004-02-01), Dean et al.
patent: 2004/0053943 (2004-03-01), Adams et al.
patent: 2004/0127496 (2004-07-01), Dean et al.
patent: 2004/0192689 (2004-09-01), Dean et al.
patent: 2004/0198730 (2004-10-01), Dean et al.
patent: 2004/0209883 (2004-10-01), Bamford et al.
patent: 2004/0235843 (2004-11-01), Bamford et al.
patent: 2004/0248896 (2004-12-01), Dean et al.
patent: 2004/0254186 (2004-12-01), Dean et al.
patent: 2 306 108 (1994-04-01), None
patent: WO 97/12876 (1997-04-01), None
patent: WO 99/32436 (1997-04-01), None
patent: WO 99/61437 (1999-12-01), None
patent: WO 02/39954 (2002-05-01), None
D.C. Heimbrock et al., Identification of Potent, Selective Inhibitors of Raf Protein Kinase, Amer. Assoc. for Cancer Res., New Orleans, Apr. 1998.
N.J. Liverton et al., Design and Synthesis of Potent, Selective and Orally Bioavailable Tetrasubstituted Imidazoles of p38 Mitogen Activated Protein Kinase., J. Med. Chem., 1999, 42, 2180-2190.
J. Lisnock et al., Molecular Basis for p38 Protein Kinase Inhibitor Specificity, BioChemistry, 1998, 37, 16573-16581.
L.M. Toledo et al., The Structure-Based Design of ATP-Site Directed Protein Kinase Inhibitors, Current Medicinal Chemistry, 1999, 6, 775-805.
Stover D.R. et al., Recent Advances in protein Kinase inhibition: Current Molecular Scaffolds Used for Inhibitor Synthesis, Current Opinion in Drug Discovery and Development, 1999, 2(4), 274-285.
F.G. Salituro et al., Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Disease, Current Medicinal Chemistry, 1999, 6, 807-823.
J.L. Adams et al., Recent Progress Towards the Identification of Selective Inhibitors of Serine/Theronine Protein Kinases, Current Opinion in Drug Discovery and Development, 1999, 2(2), 96-109.
Hall-Jackson, C.A. et al., Effect of SB203580 on the Activity of c-Raf in vitro and in vivo Oncogene, (1999) 18, 2047-2054.
J. C. Boehm et al., New Inhibitors of p38 Kinase, Expert Opinion on Therapeutic Patents, (2000), 10, (1).
C. Garcia-Echeverria et al., ATP Site Directed Competitive and Irreversible Inhibtiors of Protein Kinase, Med. Res. Reviews, 2000, 20(1), 28-57.
Wang, Z. et al., Structural Basis of Inhibitor Selectivity in MAP Kinases, Structure, Sep. 15, 1998, 6: 1117-1128.
K. Lackey et al., The Discovery of Potent cRaf1 Kinase Inhibitors, Bioorganic & Medical Chemistry Letters, 10, (2000), 223-226.
J.L. Adams et al., Pyrimidinylimidazole Inhibitors of CSBP/p38 Demonstrating Decreased Inhibition of Hepatic Cytochrome p450 Enzymes, Bioorganic & Medical Chemistry Letters, 8 (1998), 3111-3116.
T.F. Gallagher et al., Regulation of Stress-Induced Cytokine Production by Pyridinylimidazole: Inhibition of CSBP Kinase, Bioorganic & Medical Chemistry, vol. 5, No. 1, 49-64 1997.
J. C. Boehm et al., 1-Substituted 4-Aryl-5-Pyridinylimidazoles: A New Class of Cytokine Suppressive Drugs with Low 5-Lipoxygenase and Cycloxygenase Inhibitory Potency, J. Med. Chem., 1996, 39, 3929-3937.
A. Cuenda et al., SB203580 is a Specific Inhibitor of a MAP Kinase Homologue Which Is Stimulated By Cellular Stresses and Interleukin-1, FEBS Letters, 364, (1995), 229-233.
J. C. Lee et al., p 38 Mitogen-Activated Protein Kinase Inhibitors- Mechanisms and Therapeutic Potentials, Pharmacol. Ther., vol. 82, Nos. 2-3, 389-397, 1999.
Young, P. R. et al., Pyridinyl Imidazole Inhibitors of p38 Mitogen-activated Protein Kinase Bind in the ATP Site, The Journal of Biological Chemistry, vol. 272, No. 18, May 2 Issue, 1997,12116-12121.
J. Dumas et al., Discovery of a New Class of p38 Kinase Inhibitors, Bioorganic & Medical Chemistry Letters, 10, (2000), 2047-2050.
J. Dumas et al., 1-Phenyl-5-pyrazolyl Ureas Potent and Selective p38 Kinase Inhibitors, Bioorganic & Medical Chemistry Letters, 10, (2000), 2051-2054.
L. Revesz et al., SAR of 4-Hydroxypiperidine and Hydroxyalkyl Substituted Heterocycles as Novel p38 Map Kinase Inhibitors, Bioorganic & Medical Chemistry Letters, 10, (2000), 1261-1264.
S.E. deLaszlo et al., Pyrroles and Other Heterocycles as Inhibitors of p38 Kinase, Bioorganic & Medical Chemistry Letters, 8, (1998), 2689-2694.
L. Tong et al., A Highly Specific Inhibitor of Human p38 MAP Kinase Binds in the ATP Pocket, Nature Structural Biology, vol. 4, No. 4, Apr. 1997, 311.
p38 Inhibitors Based on Pyridylurea and Pyridylacetoamide Templates, Expert Opinion on Therapeutic Patents, (2000), 10, (7), 1151-1154.
Two Novel Structural Classes of p38 Kinase Inhibitors, Expert Opinion on Therapeutic Patents, (1999) 9, (4), 477-480.
J. R. Henry et al., Potent Inhibitors of the Map Kinase p38, Bioorganic & Medical Chemistry Letters 8, (1998), 3335-3340.
J. R. Henry et al., p38 Mitogen-Activated Pprotein Kinase as a Target for Drug Discovery, Drugs of the Future, 1999, 24 (12), 1345-1354.
T.B. Lowinger et al., Discovery of a Novel Class of Potent BRAF Kinase Inhibitors: Structure Activity Relationships, 335, Clinical Cancer Research, vol. 6, Nov. 2000, (Supplement) Poster Session, 13, 4533.
D. Eberwein et al., In vivo Activity of a Raf Kinase Inhibitor in Human Tumor Xenograft Models, 406, Clinical Cancer Research, vol. 6, Nov. 2000, (Supplement) Poster Session, 17, 4547.
C.F. Claiborne et al., An Efficient Sythesis of Tertasubstituted Imidazoles from N-(2-Oxo)-Amides, Tetrahedron Letters, 39, (1998), 8939-8942.
M. Antolini et al., Analogues of 4,5-bis(3,5-Dichlorophenyl)- 2-Trifluoromethyl-1H-Imidazole as Potential Antibacterial Agents, Bioorganic & Medical Chemistry Letters, 9 (1999), 1023-1028.
M. T. Bilodeau et al., Solid-Supported Synthesis of Imidazoles: A Strategy for Direct Resin-Attachment to the Imidazole Core, J. Org. Chem., 1998, 63, 2800-2801.
P.C. Astles et al., Acyl-CoA:Cholesterol O-Acyltransferase (ACAT) Inhibitors.2.2-(1,3-Dioxan-2-yl)-4,5-Diphenyl-1H-Imidazoles as Potent Inhibitors of ACAT, J. Med.Chem., 1996, 39, 1423.
A. Tannapfel et al., Mutations of the BRAF Gene in Cholangiocarcinoma but not in Hepatoecellular Carcinoma, GUT BMJ Journals, 2003, 52, 706-712.
Y. Cohen et al., BRAF Mutation in Papillary Thyroid Carcinoma, Journal of the National Cancer Institute, vol. 95, No. 8, Apr. 16, 2003.
H. Davies et al., Mutations of the BRAF Gene in Human Cancer, Nature, vol. 417, Jun. 27, 2002, 949-954.

Affiliated with

Also associated with

Rating

Imidazol derivatives as Raf kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Imidazol derivatives as Raf kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazol derivatives as Raf kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3834950